SCHEMBL7181469

SCHEMBL7181469

COc1c(C)cc(C)c(OC)c1C(=O)P(=O)(C(=O)c1c(C)cc(C)c(C)c1C)c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
POLB P06746 2/20 0.34
KDM4E B2RXH2 1/20 0.34
PKM P14618 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
GFER P55789 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CNR1 P21554 2/20 0.33
CNR2 P34972 2/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
TAS1R2 Q8TE23 1/20 0.33
ATM Q13315 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177977 0.90 TAS1R3 (0.40) MEN1KMT2APOLBKDM4EHPGD
SCHEMBL7181616 0.89 KMT2A (0.36) MEN1KMT2APOLBKDM4EMAPT
SCHEMBL7182197 0.88 MEN1 (0.35) ABCB1MEN1KMT2APOLBKDM4E
SCHEMBL7189605 0.88 TDP1 (0.36) MEN1KMT2APOLBCYP3A4MAPT
SCHEMBL7189319 0.87 ALDH1A1 (0.46) ABCB1MEN1KMT2AKDM4EMAPT
SCHEMBL7189020 0.86 KDM4E (0.40) MEN1KMT2APOLBKDM4EPKM
SCHEMBL7181822 0.86 HPGD (0.39) ABCB1MEN1KMT2APOLBPKM
SCHEMBL7180464 0.86 KMT2A (0.34) MEN1KMT2APOLBKDM4EMAPT
SCHEMBL7174855 0.86 GFER (0.35) MEN1KMT2APOLBKDM4EMAPT
SCHEMBL7181658 0.86 CA12 (0.43) KMT2APOLBKDM4ECYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ABCB1 2890/4885MEN1 2312/4885KMT2A 1586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.